This stock is no longer traded. It was delisted on July 9, 2026. Prices stop on that date; discussion is still counted.
Generated by AI
Foxo Technologies Inc. is a pioneering biotechnology company that focuses on integrating epigenetic science with longevity science to revolutionize the life insurance industry. The firm’s primary aim is to develop and market an advanced suite of epigenetic biomarkers that can be utilized to assess the biological age and health of individuals more accurately and comprehensively. These biomarkers hold significant potential for transforming underwriting standards within life insurance, offering a more personalized and scientifically robust approach to risk assessment. Foxo Technologies operates at the intersection of technology, insurance, and health sciences, impacting these sectors by enabling more precise health evaluations and promoting preventative health strategies. With its innovative approach, the company plays a critical role in advancing personalized healthcare management and insurance, positioning itself as a leader in the integration of deep-seated scientific knowledge with the procedural rigors of risk and longevity analysis, thus marking its significance in the evolving landscape of health-tech and insurtech industries.
Website477 South Rosemary Ave.
West Palm Beach, FL, 33401
United States
Summary of Nov 6's posts. Generated by AI.
Summary of Nov 5's posts. Generated by AI.
Summary of May 6's posts. Generated by AI.
Investors talking about FOXO also mention these. Each card shows that asset’s own numbers for the past 24 hours.